Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Cash from Financing Activities: 2021-2025

Historic Cash from Financing Activities for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$519,060.

  • ProQR Therapeutics N.V's Cash from Financing Activities fell 4.34% to -$519,060 in Q3 2025 from the same period last year, while for Sep 2025 it was $75.0 million, marking a year-over-year increase of 3182.86%. This contributed to the annual value of $75.1 million for FY2024, which is 3151.58% up from last year.
  • As of Q3 2025, ProQR Therapeutics N.V's Cash from Financing Activities stood at -$519,060, which was down 56.50% from -$331,664 recorded in Q2 2025.
  • ProQR Therapeutics N.V's 5-year Cash from Financing Activities high stood at $100.4 million for Q2 2021, and its period low was -$44.1 million during Q3 2022.
  • Its 3-year average for Cash from Financing Activities is $6.5 million, with a median of -$455,186 in 2024.
  • As far as peak fluctuations go, ProQR Therapeutics N.V's Cash from Financing Activities plummeted by 258.77% in 2022, and later spiked by 6,596.56% in 2024.
  • ProQR Therapeutics N.V's Cash from Financing Activities (Quarterly) stood at $30.8 million in 2021, then plummeted by 54.44% to $14.0 million in 2022, then slumped by 108.37% to -$1.2 million in 2023, then soared by 6,596.56% to $76.3 million in 2024, then fell by 4.34% to -$519,060 in 2025.
  • Its Cash from Financing Activities was -$519,060 in Q3 2025, compared to -$331,664 in Q2 2025 and -$525,942 in Q1 2025.